Professor Siow Ming Lee

Professor Siow Ming Lee

MBBS (London), PhD, FRCP


40 years of experience
26 years as a specialist

Overall Rating

Overall Experience


Bedside Manner




Top feedback

“This professor is absolutely excellent I have been under his care for the last 9 years, and he is very understanding and caring. He really is a huge asset to the UCH and I have survived stage 4 small cell lung cancer due to prof Lee for going on 9 years “
Read more


  • Lung Cancer
  • Kaposi's Sarcoma
  • Medical Oncology
  • Mesothelioma
Show more

Languages spoken

  • English
Show more

Registered with

  • General Medical Council: 2568021
Show more

    Practices worked at

    The Princess Grace Hospital

    42-52 Nottingham Place, London, United Kingdom, W1U 5NY
    2,126 reviews

    HCA UK at University College Hospital

    15th Floor University College Hospital 235 Euston Road, London, United Kingdom, NW1 2BU
    154 reviews


    Prof Siow Ming Lee is Professor of Medical Oncology and Consultant Medical Oncologist at University College London Hospital (UCLH). He is an internationally recognised authority on lung cancer treatment and research.

    He has led several National Cancer Research Institute (NCRI) lung cancer trials over the past three decades in UK, which have changed clinical practice and improved treatment outcomes for lung cancer patients.

    His research team established the use of gemcitabine/carboplatin chemotherapy to treat lung cancer and this treatment remains the standard chemotherapy combination to treat squamous lung cancer. His innovative trials with thalidomide as a cancer weapon and the smart drug erlotinib to treat poor performance lung cancer patients received worldwide publicity including being featured on BBC Ten O’Clock News at launch. His ET trial was the first prospective biomarker chemotherapy trial with ERCC1 to select lung cancer patients for doublet chemotherapy and demonstrated that platinum combination is superior to non-platinum chemotherapy. His latest trials examine the role of atezolizumab immunotherapy to treat poor performance non-small cell lung cancer patients (IPSOS) and hydroxychloroquine to treat small cell lung cancer (Study 15). His team was also part of the international FLAURA and KEYNOTE-189 Investigators that established osimertinib and chemotherapy-pembrolizumab combination as standard first-line therapy to treat EGFR mutant and wild-type lung cancer respectively. His trials have been recognised at major international conferences with many invited Presidential, Plenary and Oral Presentations at World Lung Cancer Conference, ASCO and ESMO and resulted in several 1st or senior author publications in high impact journals. His practice-changing trials and 4* high impact research publications were used for the REF 2014 exercise which ranked UCL top for research in UK.

    Professor Lee is the Clinical Lead for the UCLH Thoracic Medical Oncology Unit and chairs the London Lung Cancer Group, which has an international research reputation. He previously was chairperson for the NCRI Lung Cancer Advanced Disease Subgroup, NCRI Brain New-agents Clinical Subgroup and committee member of CTACC, NCRI Lung, NCRI Brain and NCRI Lymphoma Groups.

    Diseases, Medical Tests and Treatments

    • Targeted therapies and immunotherapy for lung cancer 
    • Non-small cell lung cancer
    • Small lung cell cancer 
    • Malignant mesothelioma
    • Thymic carcinoma 
    • HIV-related cancers


    • Cancer Prevention and Screening
    • Oncoplastic Surgery
    Read more

    Special interests

    • Lung Cancer
    • Kaposi's Sarcoma
    • Mesothelioma
    Read more


    • MBBS (London)
    • PhD
    • FRCP
    Read more


    Powered by Doctify
    Promoting trust & transparency in healthcare